Objective: To explore the clinical efficacy of Xuefu Zhuyu (血府逐瘀, XFZY) oral liquid combined with western medicine (WM) in reversing left ventricle remodeling (LVR) after acute myocardial infarction (AMI) in patie...Objective: To explore the clinical efficacy of Xuefu Zhuyu (血府逐瘀, XFZY) oral liquid combined with western medicine (WM) in reversing left ventricle remodeling (LVR) after acute myocardial infarction (AMI) in patients and its therapeutic mechanism. Methods: Sixty patients conforming to criteria were divided into the treated group and WM control group with randomly stratified method. Thirty cases were assigned to each group, they were given XFZY + WM + general treatment and WM + general treatment respectively. Color Doppler ultrasonography was used to study the changes of LVR before and after treatment. Results: In both groups, before and after treatment the P value of such parameters as the changes of their left diastolic volume (LDV), left systolic volume (LSV), left ventricle ejection fraction (EF) was <0.05, suggesting that the difference of various parameters was significantly different; but when compared with the results of the 12th week after medications, the change of LDV, LSV, EF showed that the LDV, LSV of the treated group were lower than that of the control group, the EF of the treated group was higher than that of the control group, and the P value of various groups was all <0.05, suggesting that the different data of various groups showed significant difference. Conclusion: Conventional WM treatment and XFZY combined with WM could both, in treating AMI, effectively reverse the patients' LVR; yet the use of integrative Chinese and western medicine on reversing patients LVR showed even better results than that of simple WM treatment.展开更多
Background： Surgical ventricular restoration （SVR） has been performed to treat left ventricular （LV） aneurysm. However, there is limited analysis of changes in LV shape. This study aimed to evaluate the changes i...Background： Surgical ventricular restoration （SVR） has been performed to treat left ventricular （LV） aneurysm. However, there is limited analysis of changes in LV shape. This study aimed to evaluate the changes in LV shape induced by SVR and the effects of SVR on LV size and function for LV aneurysm. Methods： Between April 2006 and March 2015, 18 patients with dyskinetic （dyskinetic group） and 12 patients with akinetic （akinetic group） postinfarction LV anterior aneurysm receiving SVR with the Dor procedure at Chinese People＇s Liberation Army General Hospital were enrolled in this study. A retrospective analysis was carried out using data from the echocardiography database. LV shape was analyzed by calculating the apical conicity index （ACI）. LV end-diastolic volume index, end-systolic volume index, and ejection fraction （EF） were measured. One-way analysis of variance was used to compare means at different time points within each group. Results： Within one week after SVR, LV shape became more conical in the two groups （ACI decreased from 0.84 ± 0.13 to 0.69 ± 0.11 [t = 5.155, P = 0.000] in dyskinetic group and from 0.73 ± 0.07 to 0.60 ± 0.11 [t = 2.701, P = 0.026] in akinetic group; LV volumes were decreased significantly and became closer to normal values and EF was improved significantly in the two groups）. On follow-up at least one year, LV shape remained unchanged in dyskinetic group （ACI increased from 0.69 ± 0.11 to 0.74 ± 0.12, t = - 1.109, P = 0.294）, but became more spherical in akinetic group （ACI significantly increased from 0.60 ± 0.11 to 0.75 ±0.11, t = -I .880, P = 0.047）; LV volumes remained unchanged in dyskinetic group, but increased significantly in akinetic group and EF remained unchanged in the two groups. Conclusions： SVR could reshape LV to a more conical shape and a more normal size and improve LV function significantly early after the procedure in patients with dyskinetic or akinetic postinfarction LV anterior aneurysm. However, LV tends to be more spherical and enlarged in the akinetic group on at least 1-year follow-up.展开更多
Background Nowadays, the studies mainly focus on the function of decreasing the inflammatory factor and improving the functions of endothelium, but the Methods The 2-kindey, 1-clip hypertensive rats effects of statins...Background Nowadays, the studies mainly focus on the function of decreasing the inflammatory factor and improving the functions of endothelium, but the Methods The 2-kindey, 1-clip hypertensive rats effects of statins on ventricular remodeling are rarely studied. （2K1C, Goldblatt） were prepared with Sprague-Dawley （SD） rat. SD rats were randomly divided into three groups： control rats, hypertensive rats and hypertensive rats treated with atorvastatin （2 mg·kg^-1·d^-1）. After 6 weeks, systolic blood pressure （SBP） was measured using the tail-cuff method. The plasma concentration of angiotensin Ⅱ and renin activity were determined by radioimmunoassay. The heart weight, the ratio of left ventricular weight and body weight was calculated. Results The plasma concentration of angiotensin Ⅱ （106.4±7.8） ng/L and renin activity （20.6±2.4） ng/L were significantly increaed in hypertensive rats compared with normal rats [ （72.3±5.4） ng/L and （12.5±3.7） ng/L] （P 〈 0.01）. The heart weight （1.46 ± 0.09）g, the ratio 3.54±0.19 （ × 10^-3） of left ventricular weight and body weight in hypertensive rats were obviously higher than that in normal rats [（0.98±0.07）g and （2.28 ± 0.06） × 10^-3] （P 〈 0.01）. After treatment with atorvastatin, the plasma concentration of angiotensin Ⅱ （68.3 ± 6.9） ng/L and renin activity（8.7 ± 2.3 ）ng/L, heart weight（1.05± 0.04）g, the ratio 2.36 ± 0.07 （×10^-3） above were decreased significantly, there were no difference between the group of hypertensive rats and the normal. Conclusions Atorvastatin can decrease the ratio of left ventricular weight and body weight and has the effects on cardiovascular remodeling in hypertensive rats.展开更多
Background： The primary cause of ischemic heart failure （HF） is myocardial infarction （MI） resulting in left ventricle （LV） wall motion abnormality secondary to ventricular remodeling. A prospective, nonrandomi...Background： The primary cause of ischemic heart failure （HF） is myocardial infarction （MI） resulting in left ventricle （LV） wall motion abnormality secondary to ventricular remodeling. A prospective, nonrandomized study conducted in China was designed to assess safety and efficacy of the percutaneous ventricular restoration therapy using Parachute device （CardioKinetix, lnc., CA, USA） in ischemic HF patients as a result of LV remodeling after anterior wall M1. Methods： Thirty-one patients with New York Heart Association （NYHA） Class I1, I11 ischemic HF, ejection traction between 15% and 40%, and dilated akinetic or dyskinetic anterior-apical wall without the need to be revascularized were enrolled from seven sites in China from October to December 2014. The Parachute device was implanted through femoral artery. All patients received low-dose aspirin and anticoagulation with warfarin tbr at least 12 months postdevice implantation. The primary end-point was the assessment of efficacy as measured by the reduction in LV end-systolic volume index （LVESVI） against baseline LVESVI at 3 months postdevice implantation, determined by the echocardiography and measured by echocardiography core laboratory. Quality of life was assessed using EQ-SD and visual analog scale （VAS）. For quantitative data comparison, paired t-test （normality data） and signed-rank test （abnormality data） were used： application of signed-rank test was tbr the ranked data comparison. Results： A change in LVESVI as measured by echocardiography from the preimplant baseline to 3-month postdevice implantation revealed a statistically significant reduction from 77.5 ~ 20.0 ml/m-＇ to 53,1 ~ 17.0 ml/m-＂ （P 〈 0.0001 ）, The trial met its primary end-point. Of the 31 patients, the procedural success was 96.8%. Overall, NYHA HF class assessment results showed an improvement of more than halfa class at 3 months （P 〈 0.001 ）. Quality of life assessed by the VAS value increased 11.5 points （P 〈 0.01 ）, demonstrating improvement at 3 months.Conclusion： The favorable outcomes observed in the high-risk patients provide reassuring safety and efficacy data to support adoption of this technology as a therapeutic option for ischemic HF patients. Trial Registration： ClinicalTrials.gov, NCT02240940; https：// clinicaltrials.gov/ct2/show/NCT02240940.展开更多
文摘Objective: To explore the clinical efficacy of Xuefu Zhuyu (血府逐瘀, XFZY) oral liquid combined with western medicine (WM) in reversing left ventricle remodeling (LVR) after acute myocardial infarction (AMI) in patients and its therapeutic mechanism. Methods: Sixty patients conforming to criteria were divided into the treated group and WM control group with randomly stratified method. Thirty cases were assigned to each group, they were given XFZY + WM + general treatment and WM + general treatment respectively. Color Doppler ultrasonography was used to study the changes of LVR before and after treatment. Results: In both groups, before and after treatment the P value of such parameters as the changes of their left diastolic volume (LDV), left systolic volume (LSV), left ventricle ejection fraction (EF) was <0.05, suggesting that the difference of various parameters was significantly different; but when compared with the results of the 12th week after medications, the change of LDV, LSV, EF showed that the LDV, LSV of the treated group were lower than that of the control group, the EF of the treated group was higher than that of the control group, and the P value of various groups was all <0.05, suggesting that the different data of various groups showed significant difference. Conclusion: Conventional WM treatment and XFZY combined with WM could both, in treating AMI, effectively reverse the patients' LVR; yet the use of integrative Chinese and western medicine on reversing patients LVR showed even better results than that of simple WM treatment.
文摘Background： Surgical ventricular restoration （SVR） has been performed to treat left ventricular （LV） aneurysm. However, there is limited analysis of changes in LV shape. This study aimed to evaluate the changes in LV shape induced by SVR and the effects of SVR on LV size and function for LV aneurysm. Methods： Between April 2006 and March 2015, 18 patients with dyskinetic （dyskinetic group） and 12 patients with akinetic （akinetic group） postinfarction LV anterior aneurysm receiving SVR with the Dor procedure at Chinese People＇s Liberation Army General Hospital were enrolled in this study. A retrospective analysis was carried out using data from the echocardiography database. LV shape was analyzed by calculating the apical conicity index （ACI）. LV end-diastolic volume index, end-systolic volume index, and ejection fraction （EF） were measured. One-way analysis of variance was used to compare means at different time points within each group. Results： Within one week after SVR, LV shape became more conical in the two groups （ACI decreased from 0.84 ± 0.13 to 0.69 ± 0.11 [t = 5.155, P = 0.000] in dyskinetic group and from 0.73 ± 0.07 to 0.60 ± 0.11 [t = 2.701, P = 0.026] in akinetic group; LV volumes were decreased significantly and became closer to normal values and EF was improved significantly in the two groups）. On follow-up at least one year, LV shape remained unchanged in dyskinetic group （ACI increased from 0.69 ± 0.11 to 0.74 ± 0.12, t = - 1.109, P = 0.294）, but became more spherical in akinetic group （ACI significantly increased from 0.60 ± 0.11 to 0.75 ±0.11, t = -I .880, P = 0.047）; LV volumes remained unchanged in dyskinetic group, but increased significantly in akinetic group and EF remained unchanged in the two groups. Conclusions： SVR could reshape LV to a more conical shape and a more normal size and improve LV function significantly early after the procedure in patients with dyskinetic or akinetic postinfarction LV anterior aneurysm. However, LV tends to be more spherical and enlarged in the akinetic group on at least 1-year follow-up.
文摘Background Nowadays, the studies mainly focus on the function of decreasing the inflammatory factor and improving the functions of endothelium, but the Methods The 2-kindey, 1-clip hypertensive rats effects of statins on ventricular remodeling are rarely studied. （2K1C, Goldblatt） were prepared with Sprague-Dawley （SD） rat. SD rats were randomly divided into three groups： control rats, hypertensive rats and hypertensive rats treated with atorvastatin （2 mg·kg^-1·d^-1）. After 6 weeks, systolic blood pressure （SBP） was measured using the tail-cuff method. The plasma concentration of angiotensin Ⅱ and renin activity were determined by radioimmunoassay. The heart weight, the ratio of left ventricular weight and body weight was calculated. Results The plasma concentration of angiotensin Ⅱ （106.4±7.8） ng/L and renin activity （20.6±2.4） ng/L were significantly increaed in hypertensive rats compared with normal rats [ （72.3±5.4） ng/L and （12.5±3.7） ng/L] （P 〈 0.01）. The heart weight （1.46 ± 0.09）g, the ratio 3.54±0.19 （ × 10^-3） of left ventricular weight and body weight in hypertensive rats were obviously higher than that in normal rats [（0.98±0.07）g and （2.28 ± 0.06） × 10^-3] （P 〈 0.01）. After treatment with atorvastatin, the plasma concentration of angiotensin Ⅱ （68.3 ± 6.9） ng/L and renin activity（8.7 ± 2.3 ）ng/L, heart weight（1.05± 0.04）g, the ratio 2.36 ± 0.07 （×10^-3） above were decreased significantly, there were no difference between the group of hypertensive rats and the normal. Conclusions Atorvastatin can decrease the ratio of left ventricular weight and body weight and has the effects on cardiovascular remodeling in hypertensive rats.
文摘Background： The primary cause of ischemic heart failure （HF） is myocardial infarction （MI） resulting in left ventricle （LV） wall motion abnormality secondary to ventricular remodeling. A prospective, nonrandomized study conducted in China was designed to assess safety and efficacy of the percutaneous ventricular restoration therapy using Parachute device （CardioKinetix, lnc., CA, USA） in ischemic HF patients as a result of LV remodeling after anterior wall M1. Methods： Thirty-one patients with New York Heart Association （NYHA） Class I1, I11 ischemic HF, ejection traction between 15% and 40%, and dilated akinetic or dyskinetic anterior-apical wall without the need to be revascularized were enrolled from seven sites in China from October to December 2014. The Parachute device was implanted through femoral artery. All patients received low-dose aspirin and anticoagulation with warfarin tbr at least 12 months postdevice implantation. The primary end-point was the assessment of efficacy as measured by the reduction in LV end-systolic volume index （LVESVI） against baseline LVESVI at 3 months postdevice implantation, determined by the echocardiography and measured by echocardiography core laboratory. Quality of life was assessed using EQ-SD and visual analog scale （VAS）. For quantitative data comparison, paired t-test （normality data） and signed-rank test （abnormality data） were used： application of signed-rank test was tbr the ranked data comparison. Results： A change in LVESVI as measured by echocardiography from the preimplant baseline to 3-month postdevice implantation revealed a statistically significant reduction from 77.5 ~ 20.0 ml/m-＇ to 53,1 ~ 17.0 ml/m-＂ （P 〈 0.0001 ）, The trial met its primary end-point. Of the 31 patients, the procedural success was 96.8%. Overall, NYHA HF class assessment results showed an improvement of more than halfa class at 3 months （P 〈 0.001 ）. Quality of life assessed by the VAS value increased 11.5 points （P 〈 0.01 ）, demonstrating improvement at 3 months.Conclusion： The favorable outcomes observed in the high-risk patients provide reassuring safety and efficacy data to support adoption of this technology as a therapeutic option for ischemic HF patients. Trial Registration： ClinicalTrials.gov, NCT02240940; https：// clinicaltrials.gov/ct2/show/NCT02240940.
